Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Stopped The study was terminated at median 46-48 months long term follow-up and mature overall survival follow-up data.
Conditions
- Relapsed and/or Relapsed-refractory Multiple Myeloma
Interventions
- DRUG: Melflufen
- DRUG: Dexamethasone
Sponsor
Oncopeptides AB